Intravenous infusion of tocilizumab-bavi for hospitalized adults, second dose

This code represents intravenous infusion of tocilizumab-bavi (Tofidence), a biosimilar to reference tocilizumab (Actemra), administered to hospitalized adult patients. Tocilizumab is an IL-6 receptor antagonist used in the inpatient setting, most notably for cytokine release syndrome (CRS) and severe or critical COVID-19. The "-bavi" suffix designates this specific FDA-approved biosimilar product, distinguishing it from the reference biologic and other tocilizumab biosimilars.

This code applies when tocilizumab-bavi is administered via IV infusion to an adult patient in a hospital setting, such as for CRS following CAR-T cell therapy or for hospitalized patients with severe COVID-19 requiring supplemental oxygen or mechanical ventilation. Documentation should include the specific biosimilar product name and manufacturer (not just "tocilizumab"), route of administration, dose administered, and the clinical indication supporting inpatient use. Payer coverage policies may require prior authorization documentation or evidence of medical necessity tied to an approved indication.

• Do not interchange this code with codes for reference tocilizumab (Actemra) or other tocilizumab biosimilars (e.g., tocilizumab-aazg); HCPCS codes are product-specific for biosimilars, and incorrect product reporting can result in claim denial or audit risk.
• Verify the NDC on the claim aligns with tocilizumab-bavi; many payers require NDC reporting alongside the HCPCS code for biosimilar infusions to confirm the specific product dispensed.
• In the hospital outpatient setting, this code would not apply — confirm the patient status is inpatient, as the code descriptor explicitly limits use to hospitalized patients; outpatient or infusion center administration would require a different billing pathway.